SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and reports of heavy leveraged-position liquidations are driving the conversation, with traders debating whether the move marks capitulation or signals more downside. Some see a buying opportunity and expect a bounce, while others cite weak support and fear of further crypto-market losses.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention after a sharp slide alongside Bitcoin and the broader crypto market, with traders pointing to market-wide selling rather than a confirmed XRP-specific catalyst. The break below a key psychological level has fueled fears of further losses, while other traders see an oversold dip and are accumulating.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,738,272,860.16806072. The last known price of Dogecoin is 0.06457313 USD and is down -2.71 over the last 24 hours. It is currently trading on 1545 active market(s) with $672,498,596.98 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins sharp drop alongside a broader crypto selloff dominates the discussion, with traders worried about fresh multi-year lows and further losses. Others see the weakness as a buying opportunity, citing dip-buying and possible technical signs of a rebound.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,215,668.80579185. The last known price of Ethereum is 1,929.81008702 USD and is down -4.05 over the last 24 hours. It is currently trading on 14342 active market(s) with $15,325,408,368.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is caught in a broad crypto selloff, with traders citing Bitcoin weakness and forced liquidations alongside wider risk-off pressure and macro concerns. Sentiment is split between calls that the decline may be capitulation and expectations of further losses, while some traders are buying the dip.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention amid a steep pullback from recent highs, with traders discussing weakening support, possible liquidations and broader crypto-market pressure. The community is split between calling the drop an oversold buying opportunity and expecting more downside; some also point to Zcashs privacy features and network upgrades as reasons for longer-term optimism.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,140,678.86417527 in circulation. The last known price of Hedera is 0.06118377 USD and is down -3.83 over the last 24 hours. It is currently trading on 468 active market(s) with $73,346,897.90 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention after traders linked its sharp rally to Nvidias involvement in the Hedera Council and Hederas presence in Nvidias Open Agent Safety Platform. The community is split between viewing the AI association as a meaningful catalyst and calling the move hype or a sell-the-news pump as the token pulls back.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 159.21664083 USD and is down -1.76 over the last 24 hours. It is currently trading on 414 active market(s) with $110,625,382.40 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

Quant is drawing attention after a steep selloff alongside broader crypto weakness, with traders debating whether the pullback has further to run or is a buying opportunity. Many are accumulating on weakness based on the long-term tokenized-banking and Clearing House thesis, while skeptics question the tokens near-term demand before the network goes live.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,493,507.45679271 with 591,519,914.8768357 in circulation. The last known price of Solana is 77.75210106 USD and is down -4.52 over the last 24 hours. It is currently trading on 1189 active market(s) with $3,771,510,230.13 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a sharp broader crypto selloff, with traders noting heavy downside pressure and a break below a closely watched support area as Bitcoin and other major tokens also fall. The community is split between buying the dip and expecting further declines, with some attributing the weakness to political or security concerns but no single explanation emerging as consensus.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,648,344.194204 with 36,816,370,531.313927 in circulation. The last known price of Cardano is 0.16792499 USD and is down -4.07 over the last 24 hours. It is currently trading on 1752 active market(s) with $304,416,326.91 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs steep decline amid broader crypto weakness is driving bearish talk of further losses and frustration with its prolonged underperformance. Traders are split between selling or waiting for lower levels and buying the dip for a rebound; some also cite Charles Hoskinsons comments that Cardanos roadmap is complete as a source of disappointment, while bullish squeeze calls remain speculative.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows earnings update and weaker outlook have fueled a sharp selloff, with traders pointing to rising mortgage rates and a sluggish housing market as headwinds. The community is split between bearish concerns about further downside and bulls viewing the decline as a buying opportunity.

statis crypto Watchlist

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regentis Biomaterials (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC (R), its proprietary implant for repairing damaged knee cartilage, in Israel. GelrinC has received regulatory approval from Israel&#8217;s Ministry of Health for the same indication [&#8230;]

Durability as the New Standard in Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time? One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International Cartilage Summit

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC(R) [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) to Present at 2026 ThinkEquity Conference on Oct. 15

Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair

Cartilage repair is intended to do more than simply reduce pain. Ideally, proper treatment should also restore the cartilage tissue responsible for the smooth movement and durability of a healthy joint. Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing a regenerative approach designed to address that challenge&#8230; Read More&#62;&#62; This content was disseminated on behalf [&#8230;]

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with their own tradeoffs in durability, complexity, and cost. That balance [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly, nearly a half-million Americans end up with knee cartilage damage each year as a result of long-term wear and tear and every-day accidents. For decades, many available treatments [&#8230;]

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for… Read More>> This content has been disseminated on behalf of Regentis Biomaterials Ltd. […]

Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual [&#8230;]

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Neutral Sentiment

<ul class="summary-bullets"><li>On May 1, the company proposed a public offering of 3.33 million ordinary shares at an assumed price of $3 per share.</li><li>Regentis had also granted underwriters a 45-day option to purchase up to 500,000 additional shares.</li><li>Regentis’ lead therapy GelrinC is being evaluated in a Phase III trial, with more than 50% patients already enrolled.</li></ul>Shares of Regentis Biomaterials (RGNT) ripped past 850% on Monday to a fresh all-time high, as investors cheered the withdrawal of a proposed public share offering.<a href="https://stocktwits.com/symbol/RGNT">RGNT shares</a> also clocked their biggest-ever single-day gains.<h2 class="st-heading-2">RGNT Withdraws Proposed Public Offering</h2>On Monday, Regentis Biomaterials filed an application with the Securities and Exchange Commission (SEC) to withdraw its Form F-1 registration statement, indicating that it no longer plans to proceed with a proposed public offering announced last month.On May 1, the company proposed a firm-commitment public offering of 3.33 million ordinary shares at an assumed price of $3 per share, which would have raised about $10 million before expenses. The company also granted the underwriters a 45-day option to purchase up to 500,000 additional shares to cover any over-allotments.<h2 class="st-heading-2">RGNT Preparing For European Comemrcialization Of GelrinC</h2>Regentis Biomaterials is a regenerative medicine company developing tissue-repair treatments, with an initial focus on orthopedic conditions. Its lead product, GelrinC, is a hydrogel implant designed to help regenerate damaged knee cartilage.Earlier this month, the company said GelrinC was being evaluated in a Phase III U.S. trial, with more than 50% patients already enrolled. Regentis said it is positioning itself for potential European commercialization, completion of the study, and eventual FDA submission.<h2 class="st-heading-2">What Does Retail Think Of RGNT?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, while message volumes saw a mammoth 22,600% increase in the same time frame.One user expects the stock to rally even further after hours.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/656483387</stembedurl>The stock has gained more than 98% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-gains-eyes-on-breakout/cZKfp1LR73n">HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Why Did RGNT Stock Surge More Than 850% Today?

Regentis Biomaterials filed a notice to withdraw its Form F-1 registration statement, indicating that it did not wish to proceed with a proposed public offering announced last month.

Equity

Regentis Biomaterials

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.23
Prev Close	$1.25
Open	$1.24
Dividend Yield	0.00%
50-Day Moving Average	$1.62
Beta	3.08
Avg. Volume	42,127.91
PE Ratio	-0.50

52-Week High	$15.50
52-Week Low	$1.16
Market Capitalization	$8.64M
EPS (Annual)	-$2.64
Price to Book	1.12
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

RGNT Fundamentals